Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-Label, Multi-Center Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

NCT01253681 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01253681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01253681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-Label, Multi-Center Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2010
Completion date
January 31, 2015
Enrollment
27 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, fallopian tube cancer, ovarian cancer, primary peritoneal cancer